How Congress is preventing a Medicare bankruptcy during COVID-19

The novel coronavirus continues to spread throughout the country and is showing no signs of cessation. That’s bad news for seniors, and in more ways than one. Everyone knows of the disproportionate health risks the nation’s elderly face from this virus, but the threat...

The Proposed Biosimilar Shared Savings Model: A Closer Look

In recent weeks, there has been increasingly more buzz around establishing a biosimilars shared savings model for Medicare Part B drugs in the U.S. This concept has arguably been in the works — or at least on many minds — since I began writing about biosimilars in...

Choice Is Vital to Biosimilar Savings Picture

In a webinar this week, experts discussed the business dynamics that prevent providers from being able to choose the lowest-cost biosimilars. Several trastuzumab biosimilars have been launched this year, and 6 FDA-approved adalimumab biosimilars are lined up for...

Why It’s Time For A U.S. Biosimilar Shared Savings Model

Over the past few months, there’s been an increasing amount of chatter about launching a biosimilar shared savings program through the Center for Medicare and Medicaid Innovation (CMMI). As the industry continues to note the misaligned incentives in Medicare slowing...